{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T20:45:59Z","timestamp":1791319559168,"version":"4.3.1"},"reference-count":29,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T00:00:00Z","timestamp":1445299200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0141279","type":"journal-article","created":{"date-parts":[[2015,10,20]],"date-time":"2015-10-20T14:07:17Z","timestamp":1445350037000},"page":"e0141279","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":49,"title":["Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study"],"prefix":"10.1371","volume":"10","author":[{"given":"Eric A.","family":"Benson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Skaar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunlong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth P.","family":"Nephew","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Matei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,10,20]]},"reference":[{"issue":"5","key":"ref1","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/PAP.0b013e3181b4fffa","article-title":"Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems","volume":"16","author":"R Vang","year":"2009","journal-title":"Advances in anatomic pathology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"932371","DOI":"10.1155\/2010\/932371","article-title":"Ovarian cancer pathogenesis: a model in evolution","volume":"2010","author":"AM Karst","year":"2010","journal-title":"Journal of oncology"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ygyno.2010.06.003","article-title":"SGO White Paper on ovarian cancer: etiology, screening and surveillance","volume":"119","author":"JO Schorge","year":"2010","journal-title":"Gynecologic oncology"},{"issue":"1","key":"ref4","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.molonc.2013.09.001","article-title":"Plasma microRNAs predicting clinical outcome in metastatic colorectal cancer patients receiving first-line oxaliplatin-based treatment","volume":"8","author":"JB Kjersem","year":"2014","journal-title":"Mol Oncol"},{"issue":"4","key":"ref5","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrc1840","article-title":"Oncomirs\u2014microRNAs with a role in cancer","volume":"6","author":"A Esquela-Kerscher","year":"2006","journal-title":"Nature reviews Cancer"},{"issue":"8","key":"ref6","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1016\/j.biocel.2009.12.017","article-title":"Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications","volume":"42","author":"D Mezzanzanica","year":"2010","journal-title":"The international journal of biochemistry & cell biology"},{"issue":"7043","key":"ref7","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1038\/nature03702","article-title":"MicroRNA expression profiles classify human cancers","volume":"435","author":"J Lu","year":"2005","journal-title":"Nature"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1007\/s13238-012-2003-z","article-title":"Horizontal transfer of microRNAs: molecular mechanisms and clinical applications","volume":"3","author":"X Chen","year":"2012","journal-title":"Protein & cell"},{"issue":"10","key":"ref9","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1124\/dmd.113.052357","article-title":"Incubation of whole blood at room temperature does not alter the plasma concentrations of microRNA-16 and -223","volume":"41","author":"EA Benson","year":"2013","journal-title":"Drug metabolism and disposition: the biological fate of chemicals"},{"issue":"30","key":"ref10","doi-asserted-by":"crossref","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection","volume":"105","author":"PS Mitchell","year":"2008","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/2162-3619-3-14","article-title":"Circulating MicroRNAs in gynecological malignancies: from detection to prediction","volume":"3","author":"YN Zhao","year":"2014","journal-title":"Experimental hematology & oncology"},{"issue":"11","key":"ref12","doi-asserted-by":"crossref","first-page":"e77853","DOI":"10.1371\/journal.pone.0077853","article-title":"Plasma miRNAs as diagnostic and prognostic biomarkers for ovarian cancer","volume":"8","author":"H Zheng","year":"2013","journal-title":"PloS one"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/onc.2012.575","article-title":"MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine","volume":"33","author":"Y Xiang","year":"2014","journal-title":"Oncogene"},{"key":"ref14","article-title":"MicroRNA-9 promotes tumorigenesis and mediates sensitivity to cisplatin in primary epithelial ovarian cancer cells","author":"HM Zhao","year":"2015","journal-title":"Tumour Biol"},{"issue":"2","key":"ref15","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ygyno.2009.04.024","article-title":"Tumor microRNA expression patterns associated with resistance to platinum based chemotherapy and survival in ovarian cancer patients","volume":"114","author":"R Eitan","year":"2009","journal-title":"Gynecologic oncology"},{"issue":"7","key":"ref16","doi-asserted-by":"crossref","first-page":"403","DOI":"10.3109\/10520295.2013.788736","article-title":"Chemoresistance in ovarian cancer linked to expression of microRNAs","volume":"88","author":"PJ Frederick","year":"2013","journal-title":"Biotech Histochem"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1158\/0008-5472.CAN-11-3909","article-title":"Epigenetic resensitization to platinum in ovarian cancer","volume":"72","author":"D Matei","year":"2012","journal-title":"Cancer research"},{"issue":"21","key":"ref18","first-page":"6039","article-title":"Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter","volume":"60","author":"JA Plumb","year":"2000","journal-title":"Cancer research"},{"issue":"6","key":"ref19","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.3892\/ijo.2013.1896","article-title":"Gain-of-function microRNA screens identify miR-193a regulating proliferation and apoptosis in epithelial ovarian cancer cells","volume":"42","author":"H Nakano","year":"2013","journal-title":"International journal of oncology"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/1479-5876-10-241","article-title":"The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon","volume":"10","author":"PL Triozzi","year":"2012","journal-title":"Journal of translational medicine"},{"issue":"5","key":"ref21","first-page":"1277","article-title":"Increased expression of miR-148b in ovarian carcinoma and its clinical significance","volume":"5","author":"H Chang","year":"2012","journal-title":"Molecular medicine reports"},{"issue":"7353","key":"ref22","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"issue":"3","key":"ref23","doi-asserted-by":"crossref","first-page":"e34546","DOI":"10.1371\/journal.pone.0034546","article-title":"Integrated analyses of microRNAs demonstrate their widespread influence on gene expression in high-grade serous ovarian carcinoma","volume":"7","author":"CJ Creighton","year":"2012","journal-title":"PloS one"},{"issue":"4","key":"ref24","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.18632\/oncotarget.2963","article-title":"The BRCA1\/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1\/2","volume":"6","author":"Y Gu","year":"2015","journal-title":"Oncotarget"},{"key":"ref25","article-title":"MicroRNA-148a inhibits migration and invasion of ovarian cancer cells via targeting sphingosine-1-phosphate receptor 1","author":"Z Wen","year":"2015","journal-title":"Molecular medicine reports"},{"key":"ref26","article-title":"MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3","author":"S Zhao","year":"2015","journal-title":"Molecular medicine reports"},{"issue":"2","key":"ref27","first-page":"447","article-title":"Altered expression of miR-152 and miR-148a in ovarian cancer is related to cell proliferation","volume":"27","author":"X Zhou","year":"2012","journal-title":"Oncology reports"},{"issue":"2","key":"ref28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.3892\/ol.2014.2188","article-title":"Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy","volume":"8","author":"U Gezer","year":"2014","journal-title":"Oncology letters"},{"issue":"1","key":"ref29","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1007\/s10549-014-3079-3","article-title":"Changes in serum levels of miR-21, miR-210, and miR-373 in HER2-positive breast cancer patients undergoing neoadjuvant therapy: a translational research project within the Geparquinto trial","volume":"147","author":"V Muller","year":"2014","journal-title":"Breast cancer research and treatment"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0141279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T15:01:41Z","timestamp":1567263701000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0141279"}},"subtitle":[],"editor":[{"given":"Ratna B.","family":"Ray","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,10,20]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2015,10,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0141279","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,20]]}}}